Vaxcyte is transitioning from a single-product biotech to a commercial vaccine platform with its 31-valent pneumococcal conjugate vaccine, VAX-31, which offers broader serotype coverage than competitors. The vaccine is currently in pivotal Phase 3 trials for adults and Phase 2 trials for infants. Vaxcyte's strong financial position, including over $2.4 billion in cash and a completed manufacturing facility, supports simultaneous late-stage development and commercial readiness. Key upcoming milestones include the OPUS-1 Phase 3 trial results expected in Q4 2026 and additional adult and infant data in 2027, positioning Vaxcyte as a potential leader in next-generation vaccines.
The Low Earth Orbit (LEO) satellite market is projected to expand significantly, reaching a valuation of $74.54 billion by 2035 from $15.77 billion in 2025, with a CAGR of 16.8%. Growth is fueled by rising demand for broadband in underserved areas, c...
During week 21 of 2026 (May 18-22), Sampo Oyj bought back a total of 1,911,568 of its own A-shares across multiple exchanges at a weighted average price of €9.21 per share. This buyback is part of a program authorized by the company's annual general ...
Tether and the Government of Georgia announced the launch of GEL₮, a stablecoin pegged to the Georgian lari designed to enable lower transaction costs, near-instant settlement, programmable payments, and cross-border digital transfers. This initiativ...
KottonSpa™, a Texas-based newborn apparel brand, has launched a collection of essentials made entirely from 100% American-grown SUPIMA® cotton, known for its softness and durability. The collection targets infants and toddlers up to 4 years old, focu...
U.S. Secretary of State Marco Rubio indicated that a solid Iran-U.S. deal could be announced soon, possibly even today, as negotiations continue. The potential agreement focuses on reopening the Strait of Hormuz and a time-limited nuclear negotiation...
